Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women
Open Access
- 30 April 2013
- journal article
- research article
- Published by Elsevier BV in The Breast
- Vol. 22 (2), 121-129
- https://doi.org/10.1016/j.breast.2013.01.014
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Adjuvant aromatase inhibitor therapy: Outcomes and safetyCancer Treatment Reviews, 2010
- Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: Meta-analyses of monotherapy, sequenced therapy and extended therapyThe Breast, 2010
- Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancerCancer Treatment Reviews, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patientsCancer Treatment Reviews, 2006
- Immunohistochemistry of Estrogen and Progesterone Receptors ReconsideredAmerican Journal of Clinical Pathology, 2005
- Tamoxifen in the Treatment of Breast CancerThe New England Journal of Medicine, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998